View from the Thoraxcenter: ESC 23 Late-breaking Science Wrap Up
Published: 06 September 2023
-
Views:
2753 -
Likes:
7
-
Views:
2753 -
Likes:
7
-
Up Next
-
4m 50sPart 2 | Session 7 ECLS-Shock: Extracorporeal Life Support in Cardiogenic Shock
-
2m 30sPart 2 | Session 8 EARLY-UNLOAD: Early LA Septostomy vs Conventional Approach After VA-ECMO
-
3m 54sPart 2 | Session 9 STOPDAPT-3: Short and Optimal Dual Antiplatelet Therapy Duration
-
2m 37sPart 2 | Session 10 ARREST: Expedited Transfer to Cardiac Arrest Center for OHCA
-
1m 59sPart 2 | Session 11 MULTISTARS AMI: Immediate vs Staged Revascularization in Acute MI
-
3m 54sPart 2 | Session 12 2023 ESC Guidelines for the Management of ACS
-
2m 32sPart 2 | Session 13 Meta-analysis of iFR-SWEDEHEART and DEFINE FLAIR
-
3m 7sPart 2 | Session 14 FIRE: Complete or Culprit-Only PCI in Older Patients with MI
-
3m 31sPart 2 | Session 15 NOTION: Nordic Aortic Valve Intervention
-
47m 55sPart 1 View from the Thoraxcenter: ESC 23 Late-breaking Science Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
2m 25sPart 2 | Session 1 GUIDE-DES: Quantitative Coronary Angiography vs Intravascular Ultrasound for DES Guidance Nicolas M Van Mieghem, Joost Daemen
-
4m 14sPart 2 | Session 2 ILUMIEN IV: OCT-Guided Stent vs Angiography Nicolas M Van Mieghem, Joost Daemen
-
4m 19sPart 2 | Session 3 OCTOBER: OCT vs Angiography for Complex Bifurcation PCI Nicolas M Van Mieghem, Joost Daemen
-
2m 55sPart 2 | Session 4 OCTIVUS: OCT-Guided vs IVUS-Guided PCI Nicolas M Van Mieghem, Joost Daemen
-
2m 46sPart 2 | Session 5 OCT Vs IVUS Vs Angiography Guidance Nicolas M Van Mieghem, Joost Daemen
Overview
What are the take-home messages from ESC 2O23?
Join us as we delve into the pivotal results that ignited debates and discussions at ESC Congress 2023. Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) return with their "View from the Thoraxcenter" review, where they analyse the hot line and late-breaking trials presented in Amsterdam.
In this ESC 2023 wrap-up, Prof Van Mieghem and Dr Daemen will dissect the data, evaluating real-world applicability, and distilling findings into actionable insights for clinical practice.
You can either opt to view the comprehensive wrap-up encompassing new data from 15 studies, or you may select and explore the specific studies that pique your interest.
More from this programme
Part 1
Complete Wrap Up
Part 2
ESC 23 Wrap Up by Studies
About the episode
Prof Nicolas Van Mieghem and Dr Joost Daemen discuss the new data from the HEART-FID trial (NCT03037931).
The aim of this study is to assess the effectiveness and safety of intravenous (IV) ferric carboxymaltose (FCM) therapy in comparison to a placebo for the treatment of individuals with heart failure, characterized by a reduced ejection fraction and iron deficiency.
Faculty Biographies
Nicolas M Van Mieghem
Medical Director
Prof Nicolas Maria Van Mieghem is an Interventional cardiologist at Thoraxcenter, Erasmus MC, Rotterdam, NL decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them". His father was a general cardiologist and one of his biggest influences early in his career.
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
His current research focuses on cerebral embolic protection during TAVI and the search for improved…
Joost Daemen
Interventional Cardiologist
Dr Joost Daemen, MD, PhD is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam.
Dr Daemen is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.
Comments